The metabolic profiles of Chinese patients treated with second-generation antipsychotic (SGA) medication and first-generation antipsychotic (FGA) medication were compared. The sample comprised 99 patients treated with SGA (risperidone, olanzapine and ziprasidone) and 99 with FGA (chlorpromazine, haloperidol and trifluoperazine) from the outpatient clinic of a teaching hospital in Hong Kong. The most frequent psychiatric diagnosis was schizophrenia, followed by affective disorder and other psychiatric diagnoses. Subjects were measured for body weight, body height, fasting lipid and glucose levels. SGA was associated with higher LDL-cholesterol level than FGA. Individual comparison of different antipsychotics showed that patients on olanzapin...
Second generation antipsychotic medications (SGA), developed and utilized since the 1980s, have larg...
Background: Studies from the Western world have shown that antipsychotic medications in psychiatric ...
The introduction of second-generation antipsychotics (SGAs) over the past 2 decades generated consid...
OBJECTIVE: To further define the metabolic profiles of second-generation antipsychotics during the t...
Objective: To compare the effect of olanzapine with that of risperidone on weight change among Chine...
Artículo de publicación ISISecond generation antipsychotics (SGAs), such as clozapine, olanzapine, r...
This study aimed to assess the differential effects of first-generation (FGA) and second-generation ...
Objective: Metabolic and other medical conditions are frequently comorbid with schizophrenia. As the...
BACKGROUND: Second generation antipsychotics (SGA) have demonstrated several advantages over first g...
Epidemiological studies have demonstrated a relevant increased risk of diabetes in schizophrenic pat...
Schizophrenia is associated with an increased risk of metabolic disorders such as diabetes, dyslipid...
Background. Second generation antipsychotics (SGAs) are used widely for the treatment of schizophren...
Antipsychotic therapy forms the cornerstone of treatment for people with severe mental illness. Seco...
Introduction: Olanzapine is one of the most commonly used atypical antipsychotic and is associated w...
Abstract Background Patients with schizophrenia have an increased prevalence of metabolic disturbanc...
Second generation antipsychotic medications (SGA), developed and utilized since the 1980s, have larg...
Background: Studies from the Western world have shown that antipsychotic medications in psychiatric ...
The introduction of second-generation antipsychotics (SGAs) over the past 2 decades generated consid...
OBJECTIVE: To further define the metabolic profiles of second-generation antipsychotics during the t...
Objective: To compare the effect of olanzapine with that of risperidone on weight change among Chine...
Artículo de publicación ISISecond generation antipsychotics (SGAs), such as clozapine, olanzapine, r...
This study aimed to assess the differential effects of first-generation (FGA) and second-generation ...
Objective: Metabolic and other medical conditions are frequently comorbid with schizophrenia. As the...
BACKGROUND: Second generation antipsychotics (SGA) have demonstrated several advantages over first g...
Epidemiological studies have demonstrated a relevant increased risk of diabetes in schizophrenic pat...
Schizophrenia is associated with an increased risk of metabolic disorders such as diabetes, dyslipid...
Background. Second generation antipsychotics (SGAs) are used widely for the treatment of schizophren...
Antipsychotic therapy forms the cornerstone of treatment for people with severe mental illness. Seco...
Introduction: Olanzapine is one of the most commonly used atypical antipsychotic and is associated w...
Abstract Background Patients with schizophrenia have an increased prevalence of metabolic disturbanc...
Second generation antipsychotic medications (SGA), developed and utilized since the 1980s, have larg...
Background: Studies from the Western world have shown that antipsychotic medications in psychiatric ...
The introduction of second-generation antipsychotics (SGAs) over the past 2 decades generated consid...